Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study

Trial Locations (1)

Many Locations